Business
Block Listing Return
Cambridge Cognition Holdings plc has filed a block listing return for its share options scheme, reporting that as of March 31, 2026, there were 466,316 ordinary shares remaining unallotted under the scheme. This figure represents the balance from the previous return of 466,316 shares, with no increase to the block scheme and no securities issued or allotted during the period from October 1, 2025, to March 31, 2026. Disclaimer*
About this update from Cambridge Cognition Holdings Plc
1 April 2026 Cambridge Cognition Holdings plc ("Cambridge Cognition", the "Company" or the "Group") Block Listing Return The Company makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings: Name of applicant : Cambridge Cognition Holdings plc Name of scheme: Share Options Period of return: From: 1 October 2025 To: 31 March 2026 Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission: 1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on 23 March 2023 Balance of unallotted securities under scheme(s) from previous return: 466,316 ordinary shares Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil Less: Number of securities issued/allotted under scheme(s) during period: Nil Equals: Balance under scheme(s) not yet issued/allotted at end of period: 466,316 ordinary shares Name of contact: Simon McKeating Telephone number of contact: +44 (0)1223 810700 Enquiries: Cambridge Cognition Holdings plc Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer Adam Michael, Head of Corporate Communications Tel: +44 1223 810700 [email protected] Panmure Liberum Limited (NOMAD & Joint Broker) Will Goode / Mark Rogers / Freddy Crossley Rupert Dearden Tel: +44 20 7886 2968 (Corporate Finance) (Corporate Broking) Singer Capital Markets Limited (Joint Broker) Amber Higgs / James Serjeant / Daniel Ingram Tel: +44 20 7496 3000 ABOUT CAMBRIDGE COGNITION AND CANTAB PATHWAY ™ Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments support scientific discovery, accelerate drug development and improve patient care. The Company has developed a suite of touchscreen and voice-based cognitive assessments delivered under the CANTAB and Winterlight brands. These assessments are designed to: ● require minimal specialist administration ● deliver objective results in real time or shortly after completion ● reduce administrator bias ● support longitudinal monitoring of cognitive function Assessment results can be presented in formats appropriate for both consumers in home-use settings and healthcare professionals in clinical or research environments. CANTAB Pathway™ is Cambridge Cognition's latest scalable cognitive assessment solution, structured as an escalating series of tasks for use in consumer and healthcare settings: ● CANTAB One™ - a brief assessment of overall cognitive function ● CANTAB Insight™ - a three-task battery providing deeper insight across five cognitive sub-domains ● CANTAB Plus™ - specialist disease-specific modules for use by appropriately qualified healthcare professionals, covering eight indications including Parkinson's disease, ADHD, multiple sclerosis, Huntington's disease, schizophrenia, depression, and Alzheimer's disease and related dementias For further information, visit: www.cambridgecognition.com
View stock analysis, news, and events for Cambridge Cognition Holdings Plc